about
sameAs
The urgent need to recover MHC class I in cancers for effective immunotherapyAlternative Antigen Processing for MHC Class I: Multiple Roads Lead to RomeA novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigensDesign of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100Proline substitution independently enhances H-2D(b) complex stabilization and TCR recognition of melanoma-associated peptidesThe MHC Class I Cancer-Associated Neoepitope Trh4 Linked with Impaired Peptide Processing Induces a Unique Noncanonical TCR ConformerCharacterization of antigen-specific immune responses induced by canarypox virus vaccinesThe nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defectsGenetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.Inhibition of CSF-1R supports T-cell mediated melanoma therapyPromiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes.Limited density of an antigen presented by RMA-S cells requires B7-1/CD28 signaling to enhance T-cell immunity at the effector phaseInfiltrating CTLs are bothered by HLA-E on tumors.Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating LeukocytesTumor eradication by wild-type p53-specific cytotoxic T lymphocytes.TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanomaThe positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity.The other Janus face of Qa-1 and HLA-E: diverse peptide repertoires in times of stress.Strategies to counteract MHC-I defects in tumors.Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity.Importance of TAP-independent processing pathways.Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.Vaccines for established cancer: overcoming the challenges posed by immune evasion.Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire.New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation.Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma.Different expression levels of the TAP peptide transporter lead to recognition of different antigenic peptides by tumor-specific CTL.Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells.CD8+ T cell responses against TAP-inhibited cells are readily detected in the human population.In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages.Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28PD-L1 immune suppression in cancer: Tumor cells or host cells?PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells.Application of multicolor fluorescence in situ hybridization analysis for detection of cross-contamination and in vitro progression in commonly used murine tumor cell lines.
P50
Q26770165-CA1EFBC9-72BB-4FAE-A10B-1B8C9B7C52E0Q26864074-A47FD6D6-28E7-4E18-B3ED-E7BF50A3F2E2Q27023313-9BC03734-8CEF-4107-8295-F50F89AF8ADEQ27657607-E433C7D1-D7BE-479F-A900-03FB65661030Q27685375-54996BDC-40CA-4B10-B0ED-F22AB6F8E657Q27703723-C4B06D7F-A346-440A-99CA-1244D7A1EC25Q28253896-BD1843EC-7B6A-4736-9C95-8C9C20998587Q28512131-3A87C0D5-7034-42E8-BC53-57195F9E0CD6Q33849590-4A7A27D7-76A8-4652-AE99-43C6F7E690D5Q34027586-A4368276-493A-4CBB-B6FF-82F8AAA86D9EQ34259644-D524E159-EF50-446A-88E5-CE3F67EE7DA5Q34503830-D39EA141-B4E6-4C31-8FC8-7FE4A447EEECQ35081677-812B4CB7-8D90-4B8F-A2C9-93EA817BBDC6Q35407260-0A4F5D77-D34A-451D-8859-0E61D7875170Q36038385-94772FF7-F34F-48BA-80A6-DF3BBC790289Q36169054-3C8FDB6E-E193-412A-981D-317AD7300422Q36380515-A213FD1B-B193-4D62-B50C-D4340BA4241AQ36515165-DE90C8F4-80B4-4125-A957-F5AD3039E7C8Q36545890-81E4C664-57A1-413B-9FCB-1ADFE71510F9Q36772177-11833FE6-A650-49FB-9912-BC63D3F1A728Q37167857-FE9D2E6A-7C00-476A-A852-C6C7A3BB8D73Q37776563-72DE3DDD-C98A-4676-9634-EC07BE29567EQ37836060-716E5A6B-905E-42FA-9017-56057442530AQ37997195-A1AB4DF7-A809-479B-9D27-1889AEDC7495Q38062737-009E540F-2842-4D59-9EFE-78E203F808BAQ38109300-879FCA30-C92B-4FEF-AA60-E3D7578DFDDFQ38769021-E096D96C-6FA9-4916-9013-1C64CAA2C1DAQ38979183-6FEDA7D0-1531-4254-9B7B-9810BE0AA345Q39094244-3D87BE15-4A4C-4A47-BAAA-B7F092AD500CQ39234034-D415F316-9B68-4D2B-8FE2-36EE0F653E60Q39453196-652F0DCA-A355-41C2-B406-D9F1498101CBQ39501048-0DCBDC11-7403-45C2-B3AD-AFA98413A9ECQ39516970-1A664BDD-6403-4E77-AA98-48BFFC305611Q39639096-7B65E05A-0B94-4006-B6DF-2F90037924C2Q39666898-30E202AB-094D-43DB-ACEC-A334DC2C7FCDQ40859882-F2194EE4-9EC9-4386-9AB3-A794A29849F1Q41252211-B76E0781-4DCA-472B-98E6-C0F77BF8A48FQ42289790-A6D5D4F5-73ED-451C-B666-45F9D9359EDCQ42618400-56DCAF51-05F8-4DD4-9869-89659DEA6BB3Q42693596-4D1DB6D8-B181-47E0-8D1A-D77E9D7D6C81
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Thorbald van Hall
@ast
Thorbald van Hall
@en
Thorbald van Hall
@es
Thorbald van Hall
@nl
Thorbald van Hall
@sl
type
label
Thorbald van Hall
@ast
Thorbald van Hall
@en
Thorbald van Hall
@es
Thorbald van Hall
@nl
Thorbald van Hall
@sl
prefLabel
Thorbald van Hall
@ast
Thorbald van Hall
@en
Thorbald van Hall
@es
Thorbald van Hall
@nl
Thorbald van Hall
@sl
P106
P1153
6602216118
P21
P31
P496
0000-0002-9115-558X